Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer

BACKGROUND: We aimed to explore a novel therapeutic strategy to conquer acquired resistance to second generation EGFR-TKI afatinib in EGFR-mutant NSCLC. METHODS: Firstly, we established afatinib-resistant cell lines using increasing concentrations of afatinib. Secondly, we over-expressed or silenced...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongye, Wang, Ruiyu, Wang, Mingxia, Luo, Judong, Liu, Changmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798064/
https://www.ncbi.nlm.nih.gov/pubmed/35117421
http://dx.doi.org/10.21037/tcr.2019.12.49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798064/
https://www.ncbi.nlm.nih.gov/pubmed/35117421
http://dx.doi.org/10.21037/tcr.2019.12.49

Ejemplares similares